

# Fronodoside A Suppressive Effects on Lung Cancer Survival, Tumor Growth, Angiogenesis, Invasion, and Metastasis

Samir Attoub<sup>1\*</sup>, Kholoud Arafat<sup>1</sup>, An Gélaude<sup>2</sup>, Mahmood Ahmed Al Sultan<sup>1</sup>, Marc Bracke<sup>2</sup>, Peter Collin<sup>3</sup>, Takashi Takahashi<sup>4</sup>, Thomas E. Adrian<sup>5</sup>, Olivier De Wever<sup>2</sup>

**1** Department of Pharmacology & Therapeutics, Faculty of Medicine & Health Sciences, U. A. E. University, Al-Ain, United Arab Emirates, **2** Laboratory of Experimental Cancer Research, University Hospital, Gent, Belgium, **3** Coasts Bio Resources, Stonington, Maine, United States of America, **4** Division of Molecular Carcinogenesis, Center for Neurological Diseases and Cancer, Nagoya University Graduate School of Medicine, Nagoya, Japan, **5** Department of Physiology, Faculty of Medicine & Health Sciences, U. A. E. University, Al-Ain, United Arab Emirates

## Abstract

A major challenge for oncologists and pharmacologists is to develop less toxic drugs that will improve the survival of lung cancer patients. Fronodoside A is a triterpenoid glycoside isolated from the sea cucumber, *Cucumaria frondosa* and was shown to be a highly safe compound. We investigated the impact of Fronodoside A on survival, migration and invasion *in vitro*, and on tumor growth, metastasis and angiogenesis *in vivo* alone and in combination with cisplatin. Fronodoside A caused concentration-dependent reduction in viability of LNM35, A549, NCI-H460-Luc2, MDA-MB-435, MCF-7, and HepG2 over 24 hours through a caspase 3/7-dependent cell death pathway. The IC50 concentrations (producing half-maximal inhibition) at 24 h were between 1.7 and 2.5  $\mu\text{M}$  of Fronodoside A. In addition, Fronodoside A induced a time- and concentration-dependent inhibition of cell migration, invasion and angiogenesis *in vitro*. Fronodoside A (0.01 and 1 mg/kg/day i.p. for 25 days) significantly decreased the growth, the angiogenesis and lymph node metastasis of LNM35 tumor xenografts in athymic mice, without obvious toxic side-effects. Fronodoside A (0.1–0.5  $\mu\text{M}$ ) also significantly prevented basal and bFGF induced angiogenesis in the CAM angiogenesis assay. Moreover, Fronodoside A enhanced the inhibition of lung tumor growth induced by the chemotherapeutic agent cisplatin. These findings identify Fronodoside A as a promising novel therapeutic agent for lung cancer.

**Citation:** Attoub S, Arafat K, Gélaude A, Al Sultan MA, Bracke M, et al. (2013) Fronodoside A Suppressive Effects on Lung Cancer Survival, Tumor Growth, Angiogenesis, Invasion, and Metastasis. PLoS ONE 8(1): e53087. doi:10.1371/journal.pone.0053087

**Editor:** Srikumar P. Chellappan, H. Lee Moffitt Cancer Center & Research Institute, United States of America

**Received:** June 13, 2012; **Accepted:** November 27, 2012; **Published:** January 8, 2013

**Copyright:** © 2013 Attoub et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Funding:** This work was financially supported by the FMHS grant number NP/08/27 (SA), the UAE University grant under a contract no. 01-04-8-11/09 (SA), the Terry Fox Fund for Cancer Research (SA and TA), the UAEU-NRF 09/10 grant number 21MO72 (SA), and the Maine Technology Institute, Gardiner, Maine, USA, and the National Cancer Institute, RAPID Program (PC). The funding agencies had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Competing Interests:** Peter Collin is director, laboratory manager, employee and stock-holder of Coasts Bio Resources, a Maine, USA Corporation. Thomas Adrian and Peter Collin are co-inventors of a United States patent describing Fronodoside A and other sea cucumber glycosides as putative anti-cancer agents, and may benefit financially if Fronodoside A becomes a drug for human cancers. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.

\* E-mail: [samir.attoub@uaeu.ac.ae](mailto:samir.attoub@uaeu.ac.ae)

## Introduction

Lung cancer is the most common form of cancer with one of the highest mortality rates in the world. Targeted therapies for selected subgroups of patients constitute a remarkable progress in the treatment of lung cancer. However, despite these advances, controversies remain, patients die, and a cure remains elusive [1]. Natural compounds are emerging as a new generation of anticancer agents with limited toxicity in cancer patients [2,3]. They can have high value in tumors resistant to classical chemotherapies or resistant to tyrosine kinase inhibitors such as gefitinib

Sea cucumbers have been valued for hundreds of years in the Chinese diet as a food delicacy, as well as a medicine for a wide variety of diseases. In the United States and Canada, sea cucumber tissues are dried, pulverized and encapsulated as nutraceuticals for over-the-counter dietary health supplements, primarily directed at inflammatory conditions in humans and

companion animals [4]. Fronodoside A is a triterpenoid glycoside isolated from the Atlantic cucumber, *Cucumaria frondosa*. (See [5] for chemical structure). Recent studies demonstrate that low concentrations of Fronodoside A inhibit the growth and induced apoptosis of human pancreatic, leukemia and breast cancer cells via caspase activation [6–8].

The chemotherapeutic agents currently in use for lung cancer are still unsatisfactory due to associated co-lateral toxicity and drug-induced resistance [9–11] which motivate our investigation of the impact of Fronodoside A on human non-small cell lung cancer survival, migration and invasion *in vitro*, and on tumor growth, metastasis and angiogenesis *in vivo* alone and in combination with cisplatin.

## Materials and Methods

### Cell culture and reagents

Human lung cancer cells LNM35 (NSCLC) [12], A549 and NCI-H460-Luc2 (Caliper LifeSciences, US) were maintained in RPMI 1640 (Invitrogen, Paisley, UK), human melanoma MDA-MB-435, human mammary adenocarcinoma cells MCF-7, and human hepatoma cells HepG2 were maintained in DMEM (Invitrogen, Paisley, UK). All media were supplemented with antibiotics (penicillin 50 U/ml; streptomycin 50 µg/ml) (Invitrogen, Cergy Pontoise, France) and with 10% fetal bovine serum (FBS, Biowest, Nouaille, France). EndoGRO™ Human Umbilical Vein Endothelial Cells (HUVECs) (Millipore, Temecula, CA) were maintained in EndoGRO™-MV-VEGF Complete Media Kit (Millipore, Temecula, CA). Cisplatin was purchased from Sigma-Aldrich (Sigma-Aldrich, Saint-Quentin Fallavier, France). Fronodoside A was purified from *Cucumaria frondosa*, harvested near Stonington, Maine and the purity (99.9%) confirmed by NMR as previously described [13,14].

### Cellular viability

Cells were seeded at a density of 5,000 cells/well into 96-well plates. After 24 h, cells were treated for another 24 h with different concentrations of Fronodoside A (0.01–5 µM), in triplicate. Control cultures were treated with 0.1% DMSO. The effect of Fronodoside A on cell viability was determined using a CellTiter-Glo Luminescent Cell Viability assay (Promega Corporation, Madison, USA), based on quantification of ATP, which signals the presence of metabolically active cells. The luminescent signal was measured using the GLOMAX Luminometer system. Data were presented as proportional viability (%) by comparing the treated group with the untreated cells, the viability of which is assumed to be 100%.

### Caspase 3/7 activity

LNM35 cells were seeded at the density of 5,000 cells/well into 96-well plate and treated with Fronodoside A (1–2.5 µM) for 2 and 24 h, in triplicate. Caspase-3/7 activity was measured using a luminescent Caspase-Glo 3/7 assay kit following the manufacturer's instructions (Promega Corporation, Madison, USA). Caspase reagent was added and the plate was mixed using an orbital shaker and incubated for 2.5 h at room temperature. Luminescence was measured using a GLOMAX Luminometer system.

### Wound healing motility assay

LNM35 cells were grown in six-well tissue culture dishes until confluence. Cultures were incubated for 10 min with Moscona buffer. A scrape was made through the confluent monolayer with a plastic pipette tip of 1 mm diameter. Afterwards, the dishes were washed twice and incubated at 37°C in fresh RPMI containing 10% fetal bovine serum in the presence or absence of the non-toxic concentrations of Fronodoside A (0.1–0.5 µM). At the bottom side of each dish, two arbitrary places were marked where the width of the wound was measured with an inverted microscope (objective ×4) (Olympus 1X71, Japan). Motility was expressed as the average ± S.E.M of the difference between the measurements at time zero and the 6, 24 and 30 h time period considered.

### Matrigel invasion assay

The invasiveness of the lung cancer cells LNM35 treated with Fronodoside A (0.1–1 µM) was tested using BD Matrigel Invasion Chamber (8-µm pore size; BD Biosciences, Le Pont de Claix, France) according to manufacturer's protocol. The PI3 kinase inhibitor LY294002 (20 µM) was used as a positive inhibitor of


cellular invasion. Briefly, Cells ( $1 \times 10^5$  cells in 0.5 mL of media and the indicated concentration of Fronodoside A) were seeded into the upper chambers of the system, the bottom wells in the system were filled with RPMI supplemented with 10% fetal bovine serum as a chemo-attractant and then incubated at 37°C for 24 h. Non-penetrating cells were removed from the upper surface of the filter with a cotton swab. Cells that have migrated through the Matrigel were fixed with 4% formaldehyde, stained with DAPI and counted in 25 random fields under a microscope. The assay was carried out in duplicate and repeated three times for quantitative analysis.

### Chorioallantoic membrane (CAM) angiogenesis assay

This assay was performed as described previously [15], with some modifications. Briefly, fertilized eggs were incubated for 3 days at 37, 8°C with a humidity of 48%. On day 4, albumen was removed to detach the shell from the developing CAM and a window was made in the eggshell, exposing the CAM, and covered with a breathing film (suprasorb F®). The eggs were returned to the incubator until day 10, prior to application of the test compounds. Test compound and control compound (DMEM without 10% FBS) dissolved in DMEM without 10% FBS were poured onto separate sterile discs (12 mm diameter), which were allowed to dry under sterile conditions. A solution of cortisone acetate (125 µg/disc) was poured onto all discs to prevent an inflammatory response. Test discs probed with recombinant human bFGF (Peprotech) served as a control for angiogenesis stimulation. On each CAM, the disc containing control compound and the disc containing test compound were placed at a distance of 1 cm. The windows were covered and the eggs were incubated until day 14, before assessment of angiogenesis. Therefore, the eggs were flooded with 10% buffered formalin and the eggs were kept at room temperature for at least 20 minutes. The CAM, the area of the discs included, was placed in a petri dish with 10% buffered formalin. The plastic discs were removed and phase-contrast pictures of the area of the plastic discs were taken. The vascular index was measured as described previously [16]. Vascular intersections on a grid containing three concentric circles (6, 8 and 10 mm diameter with as center the center of the disc) were counted. The angiogenic index =  $(t-c)/c$ , with  $t$  the number of intersections in the area covered by the test disc and  $c$  the number of intersections in the area covered by the control disc in the same egg. The Mann-Whitney U-test was used for statistical analysis ( $p < 0.05$ ).

### Vascular tube formation assay

Assessment of *in vitro* capillary formation used Matrigel (Becton Dickinson, Le Pont de Claix, France). Matrigel is a squamous cell carcinoma basement membrane matrix composed primarily of collagen IV, laminin, entactin, and heparan sulfate proteoglycans. The Matrigel matrix was thawed, gently mixed to homogeneity using cooled pipettes, and diluted v/v with the EndoGRO™-MV-VEGF Complete Media Kit medium (Millipore, Temecula, CA, USA). Matrigel, 50 µl/well, supplemented with angiogenic peptides and other effectors was used to coat the wells of 96-well plates. The plate was then incubated for one hour at 37°C to allow the matrix solution to solidify prior to treatment. HUVECs (at a density of about  $4 \times 10^4$  cells/well and the indicated concentration of Fronodoside A) were plated to each well and incubated for 8 h at 37°C in 0.1 mL of EndoGRO™-MV-VEGF Complete Media Kit medium (Millipore, Temecula, CA, USA). Then cells were photographed using an inverted phase contrast photomicroscope. The tubular network growth area was compared in control and inhibitor-treated Matrigel matrix. Tube formation was quantified by counting the number of tube-like structures formed in each




**Figure 1. Inhibition of cellular viability by Fronodoside A.** Exponentially growing LNM35 (A), A549 (B), NCI-H460-Luc2 (C), MDA-MB-435 (D), MCF-7 (E), and HepG2 (F) cells were treated with vehicle (0.1% DMSO) and the indicated concentrations of Fronodoside A. Viable cells were assayed as described in Materials and Methods. All experiments were repeated at least three times. *Columns*, mean; *bars*, S.E.M. \*\*Significantly different at  $P < 0.01$ , \*\*\*Significantly different at  $P < 0.001$ . doi:10.1371/journal.pone.0053087.g001


well. The effect of Fronodoside A on viability of the HUVEC was determined using a CellTiter-Glo Luminescent Cell Viability assay (Promega Corporation, Madison, USA), as previously described for the cancer cells.

#### Tumor growth and metastasis assay

The animal experiments were performed in accordance with the protocol approved by the animal ethics committee and the Institutional Animal Care at the Faculty of Medicine & Health Sciences/UAE University. Six-week-old athymic NMRI female nude mice (nu/nu, Charles River, Germany) were housed in filtered-air laminar flow cabinets and handled under aseptic conditions. Procedures involving animals and their care were conducted in conformity with Institutional guidelines that are in compliance with Faculty of Medicine & Health Sciences, national and international laws and policies (EEC Council Directive 86/609, OJ L 358, 1, December 12, 1987; and NIH Guide for Care and Use of Laboratory Animals, NIH Publication No. 85-23, 1985). LNM35 cells ( $1 \times 10^6$  cells in 200  $\mu$ l PBS) were injected subcutaneously into the lateral flank of the nude mice. One week




**Figure 2. Induction of caspase-3/7 activity** was analyzed in LNM35 cells treated for 24 h with Fronodoside A (1–2.5  $\mu$ M), normalized to the number of viable cells per well and expressed as fold induction compared with the control group. \*Significantly different at  $P < 0.05$ . doi:10.1371/journal.pone.0053087.g002




**Figure 3. Fronodoside A induces regression of established LNM35 xenografts.** A) & B) Tumor volume of LNM35 xenografts inoculated subcutaneously in nude mice and treated with Fronodoside A (0.01 and 1 mg/kg, intra-peritoneal injections, respectively) or control carrier solution alone, for a total of 25 days. Data points represent the mean  $\pm$  S.E.M. of 6 mice per group. C) & D) Tumor weight obtained from the same control and treated nude mice. Data points represent the mean  $\pm$  S.E.M. of 6 mice per group. Columns, mean; bars, S.E.M. E) & F) Body weight of these mice. Data points represent the mean  $\pm$  S.E.M. of 6 mice per group. \*Significantly different at  $P < 0.05$ . doi:10.1371/journal.pone.0053087.g003

after inoculation, when tumors had reached the volume of approximately 150 mm<sup>3</sup>, animals (six in each group) were treated in the first protocol for 25 days with Fronodoside A (0.01 and 1 mg/kg/day, ip) or carrier solution (control) in order to determine the effect of Fronodoside A alone on tumor growth

and metastasis. In the second protocol, animals were treated for only 10 days with the lowest dose of Fronodoside A (0.01 mg/kg/day, ip), cisplatin (1 mg/kg/day, ip), or with combined Fronodoside A and cisplatin treatment. Control animals were treated with carrier solution. Tumor dimensions and animal weights were




**Figure 4. The anti-angiogenic activity of Fronodoside A in the xenograft tumor:** Immuno-histochemical staining of lung xenograft tumors for CD31 (microvessel density).  
doi:10.1371/journal.pone.0053087.g004



**Figure 5. The anti-angiogenic activity of Fronodoside A in the Chorioallantoic membrane (CAM) assay *in vivo*:** CAM was treated with control (serum-free medium), 100 nM Fronodoside A, 500 nM Fronodoside A, 2 µg/mL bFGF, 2 µg/mL bFGF+500 nM Fronodoside A and the vascularization of test discs was photographed.  
doi:10.1371/journal.pone.0053087.g005





**Figure 6. Quantification of CAM angiogenesis assay:** Bars indicate angiogenic indices (%) of CAM's probed with 2  $\mu$ g/mL bFGF, 100 nM Fronodoside A, 500 nM Fronodoside A, 2  $\mu$ g/mL bFGF+500 nM Fronodoside A. Data represents mean  $\pm$  SD (Mann-Whitney U-test, \*:  $p < 0.05$ , \*\*\*:  $p < 0.01$ ). In each experiment, six eggs were tested per condition.

doi:10.1371/journal.pone.0053087.g006

measured every 3 days. Tumor volume (V) was calculated using the formula:  $V = 0.4 \times a \times b^2$ , with "a" being the length and "b" the width of the tumor. After sacrifice, the tumors and axillary lymph nodes were excised and weighed.

#### Immuno-histochemical determination of CD31/platelet-endothelial cell adhesion molecule 1 (PECAM-1) for Microvessel Density

The effect of Fronodoside A on angiogenesis was evaluated using CD31 immuno-staining. The tumor tissues were quickly frozen in isopentane at  $-130^\circ\text{C}$  and stored at  $-70^\circ\text{C}$  until further processing. Eight- $\mu\text{m}$  frozen sections were fixed in acetone, and incubated overnight with a CD31 antibody (clone MEC13.3, 1:100) (BD Pharmingen, San Jose, CA, USA). Slides were then washed three times in PBS and incubated with secondary antibody labeled with rhodamine (goat anti-rat 1:100) for one hour at room temperature. The area occupied by CD31-positive microvessels and total tissue area per section were compared between treated and control mice. All analyses were performed in a blind fashion.

Results were expressed as means  $\pm$  S.E.M. of the number of experiments. The difference between experimental and control values were assessed by ANOVA followed by Dunnett's post-hoc multiple comparison test. Tumor growth and metastasis studies were analyzed using the unpaired Student's t-test.  $P < 0.05$  indicate a significant difference.

## Results

### Effect of Fronodoside A on cellular viability

As shown in **fig. 1**, Fronodoside A concentrations (0.01–5  $\mu\text{M}$ ) caused a concentration-dependent decrease in cell viability of LNM35, A549, NCI-H460-Luc2, MDA-MB-435, MCF-7, and HepG2 cells over 24 hours. The IC<sub>50</sub> concentrations (producing half-maximal inhibition) at 24 h were in the range of 1.7 and 2.5  $\mu\text{M}$  Fronodoside A for all cell lines.

### Fronodoside A induces caspase-3/7 activation


Caspase-3/7 activity is essential in apoptotic cell death pathways. The relative activity of caspases 3/7 was analyzed in LNM35 cells treated for 2 and 24 h with Fronodoside A (1–2.5  $\mu\text{M}$ ), and normalized to the number of cells per well. As shown in **Fig. 2**, caspase 3/7 activity increased by 2.5- and 10.8-fold in LNM35 cells treated for 24 h with Fronodoside A 1 and 2.5  $\mu\text{M}$  respectively. Similar effect was observed after treatment with Fronodoside A (1–2.5  $\mu\text{M}$ ) for 2 h (data not shown).

### Impact of Fronodoside A on LNM35 xenografts

To confirm the pharmacological relevance of our *in vitro* data, the anticancer activity of Fronodoside A was investigated *in vivo* in athymic mice inoculated with LNM35 lung cancer cells. The growth of the LNM35 human tumor xenografts was monitored every third or fourth day for 25 consecutive days after daily i.p. injection of 0.01 mg and 1 mg/kg of Fronodoside A. Treatment with the lowest dose of Fronodoside A (0.01 mg/kg/day) reduced the volume of the LNM35 xenografts by 41% (**Fig. 3A**). A similar difference was also found in tumor weight at the end of the experiment (2.1+/-0.3 g versus 4.5+/-0.8 g;  $P < 0.05$ ; **Fig. 3C**). Treatment with the highest dose (100 times more) of Fronodoside A (1 mg/kg/day) reduces about 43.9% tumor volume of the LNM35 xenografts (**Fig. 3B**). Almost similar difference was found in tumor weight at the end of the experiment (3+/-0.5 g versus 4.5+/-0.8 g; **Fig. 3D**). This experiment clearly demonstrated that the lowest dose of Fronodoside A (0.01 mg/kg/day) is optimal for the inhibition of tumor growth. There were no manifest undesirable effects of Fronodoside A treatment on animal behaviour or body weight in either experiment (**Fig. 3E and 3F**). In addition, there were no visible abnormalities at necropsy, or any other obvious signs of toxicity as previously described by our team [7].

### Inhibition of angiogenesis by Fronodoside A in the xenografted tumors and the CAM assay *in vivo* and in the capillary-like structures *in vitro*

Angiogenesis is an attractive target in cancer therapy not only because it supplies oxygen and nutrients for the survival of tumor cells but also provides the route for metastatic spread of these cancer cells. First, we demonstrate that in the proliferating areas at the periphery of the tumor, microvessel density (measured by CD31 staining) was significantly reduced by Fronodoside A (0.01 mg/kg/day) (**Fig. 4, right panel**) in comparison with the control-treated tumors (**Fig. 4, left panel**). Next, we used the CAM assay involving the coordination and integration of multicellular responses during development of the chick embryo to confirm this potential anti-angiogenic effect of Fronodoside A. As shown in **Fig. 5 and 6**, bFGF (2  $\mu\text{g}/\text{ml}$ ), stimulated 15% new vessel formation with angiogenic indices statistically different compared with the control DMEM medium. Fronodoside A (100 and 500 nM) inhibited basal angiogenesis in a concentration-dependent manner with respectively 7% and 12% inhibition of angiogenic index compared to control (**Fig. 5 and 6**). The formation of new blood vessels induced by bFGF was also completely suppressed by Fronodoside A (500 nM) (**Fig. 5 and 6**). Finally, to assess whether the anti-angiogenic effect of Fronodoside A involves a direct interaction of the compound with endothelial cells, we conducted comparative studies on the formation of capillary-like structures *in vitro*, using HUVECs plated on Matrigel-coated plates. As shown in **Fig. 7A**, human endothelial cells have the ability to form capillary structures when seeded and cultured on top of Matrigel substrate. Control cells move from their initial uniform pattern of dispersed cell layers and associate to form a network of cell clusters connected by long, multicellular processes leading to the formation of tube-like structures. Addition of non-toxic concentrations of Fronodoside A (0.01–1  $\mu\text{M}$ ) resulted in a marked inhibition of this spontaneous angiogenic phenotype (**Fig. 7A, and 7B**). Fronodoside A induced inhibition of this spontaneous angiogenic phenotype occurred without significant reduction of cell viability (**Fig. 7C**). Taken together, these data confirm a strong anti-angiogenic potential of Fronodoside A.




**Figure 7. Impact of Fronodoside A on the formation of capillary-like structures by HUVECs *in vitro*.** **A)** Patterns of angiogenesis induced by human umbilical vein endothelial cells (HUVEC) cultured on Matrigel matrix in 96-well plates in the absence or presence of the Fronodoside A. **B)** Quantification of tubular morphogenesis induced in HUVEC cells cultured in the absence or presence of Fronodoside A. Tube formation was determined by the length of tube-like structures containing connected cells. Data are mean  $\pm$  S.E.M. from three separate experiments. Asterisks indicate that significantly different values were obtained in the presence of the indicated inhibitors vs. the corresponding control stimulation. \*\*\*Significantly different at  $P < 0.001$ . **C)** HUVEC cells were treated with vehicle (0.1% DMSO) and the indicated concentrations of Fronodoside A. Viable cells were assayed as described in Materials and Methods. All experiments were repeated at least three times. *Columns*, mean; *bars*, S.E.M. doi:10.1371/journal.pone.0053087.g007

### Fronodoside A also impairs lung cancer cell migration and invasion *in vitro* and metastasis *in vivo*

Cancer progression is associated with the abrogation of normal controls that limit cell migration and invasion, eventually leading to metastasis. Lung cancer patients are at high risk of recurrence in the form of metastatic disease. Metastasis starts with cell migration in the primary tumor, leading to local tissue invasion and entry into lymph or blood vessels. The ability of Fronodoside A to reduce cellular migration was investigated using a classic *in vitro* wound healing model. Fronodoside A reduced cellular migration of LNM35 cells in a concentration- and time-dependent manner (Fig. 8A). Similarly, Fronodoside A impaired the invasion of LNM35 cells in matrigel invasion assay (Fig. 8B). Fronodoside A

induced inhibition of cellular migration and matrigel invasion occurred without significant reduction of cell viability (Fig. 1A).

Next, we assessed the metastatic behavior of the human pulmonary cell line LNM35 by examining axillary lymph nodes. Histological examination of the lymph nodes in LNM35-bearing mice revealed the presence of LNM35 cells in all lymph nodes from both the control and Fronodoside A treated mice (data not shown). In the control-treated group, the mean lymph nodes weight was  $548.5 \pm 112.8$  mg compared with  $256 \pm 43.3$  and  $268.8 \pm 55.7$  mg in the groups treated with Fronodoside A 0.01 mg and 1 mg/kg/day, respectively (Fig. 8C and 8D).



**Figure 8. Fronodoside A also impairs lung cancer cell migration and invasion *in vitro* and metastasis *in vivo*.** **A)** Wounds were introduced in LNM35 confluent mono-layers cultured in the presence or absence (control) of Fronodoside A (0.1–0.5 μM). The mean distance that cells travelled from the edge of the scraped area for 6, 24, and 30 h at 37°C was measured in a blinded fashion, using an inverted microscope (4× magnifications). Data are means ± S.E.M. of two independent experiments. **B)** LNM35 cells were incubated for 24 h in the presence or absence of Fronodoside A (0.01–1 μM) and LY294002 (20 μM). Cells that invaded into Matrigel were scored as described in Materials and Methods. *Columns*, mean; *bars*, S.E.M. Lymph nodes metastasis weight of established human lung cancer xenografts treated with Fronodoside A 0.01 mg/kg (**C**) and 1 mg/kg (**D**) every day for 25 days. *Columns*, mean; *bars*, S.E.M. \*Significantly different at  $P < 0.05$ , \*\*Significantly different at  $P < 0.01$ , \*\*\*Significantly different at  $P < 0.001$ . doi:10.1371/journal.pone.0053087.g008

### Fronodoside A enhances the anticancer activity of cisplatin

As shown in **Fig. 9A**, daily administration of Fronodoside A to nude mice reduced the growth of LNM35 human tumor xenografts by 40.3% at day 10. Inhibition of LNM35 tumor xenograft growth by Fronodoside A was comparable with that produced by the DNA-damaging anticancer agent cisplatin (46.9%). Combined treatment of Fronodoside A with cisplatin resulted in a remarkable potentiation (67.6%;  $P < 0.05$ ) of the cisplatin therapeutic effect (**Fig. 9A**). There were no manifest side effects of the combined treatment on animal behaviour or body weight (**Fig. 9B**).


### Discussion

Despite advances in molecular biology of lung cancer, improved diagnosis, and even optimal target therapies, the current protocols for the treatment of lung cancer are still insufficient to produce striking clinical benefits and the cure of lung cancer patients remains unsuccessful. The current targeted therapy drugs develop resistance and they are very expensive and not available to the

majority of lung cancer patients in the world. Many drugs have relatively low activity; few patients are cured, with a brief, if any, increase in survival [17]. The history of anti-cancer agents, such as paclitaxel, shows that the mechanism of action was identified several years after its clinical efficacy was demonstrated. Despite not knowing the drug's mechanism of action, we believe that the *in vitro* as well as the strong *in vivo* anti-cancer effects of Fronodoside A should translate in the clinic to a new potent anti-lung cancer agent.

In the present study, we investigated the impact of Fronodoside A on lung cancer cells progression. We showed that Fronodoside A caused concentration-responsive (0.01–5 μM) decreases in viability of LNM35, A549, and NCI-H460-Luc2 cells over 24 hours through the caspase 3/7-dependent cell death pathway. The IC<sub>50</sub> concentrations (producing half-maximal inhibition) at 24 h were between 1.7 and 2.5 μM Fronodoside A. These results are consistent with previously published results that low concentration of Fronodoside A inhibits the growth of human pancreatic cancer cells and induced apoptosis through caspase 9/3/7, increased bax, decreased bcl-2 and mcl-1, and arrested cell cycle and up-regulated p21 [8], induced apoptosis in human leukemia cells via





**Figure 9. Antitumor activity of Fronodoside A alone or in combination with the anticancer drug, cisplatin, against human lung tumor xenografts in athymic nude mice.** A) Fronodoside A enhances cisplatin efficacy against NSCLC LNM35 cells growing as xenografts. B) Impact of Fronodoside A and cisplatin alone or in combination on body weight. \*Significantly different at  $P < 0.05$ . doi:10.1371/journal.pone.0053087.g009

caspace activation [6], and significantly decreases the viability of the estrogen receptor (ER)-negative MDA-MB-231 breast cancer cells by inducing apoptosis via the Caspase9-Caspase3/7 intrinsic pathway [7]. It has also been demonstrated that Frondanol A5, an impure extract of *Cucumaria frondosa* skin from which Fronodoside A is originally derived, induced growth inhibition at S and G2-M phase with a decrease in Cdc25c and an increase in p21<sup>WAF1/CIP1</sup> with significant apoptosis associated with H2AX phosphorylation and caspase-2 cleavage in the colon cancer-derived HCT116 cells [4]. A second paper also demonstrated that Frondanol-A5P, a polar precipitate sub-fraction of Frondanol-A5, inhibited proliferation and induced G2/M phase cell cycle arrest in two pancreatic cancer cells with decreased expression of cyclin A, cyclin B, and cdc25c [18]. This anticancer effect of Fronodoside A is not tissue specific, and in this context we demonstrated that Fronodoside A induced a concentration-dependent decrease in cell viability of the melanoma MDA-MB-435, the breast MCF-7, and the hepatoma HepG2 cells.

To assess the effects of Fronodoside A on lung tumor development *in vivo*, LNM35 xenografts were made in immuno-

suppressed mice. We demonstrated that intraperitoneal administration of Fronodoside A caused a strong regression of established tumors. Maximum inhibition was obtained with the low dose of 0.01 mg/kg/day for 25 days. A 100 times higher dose gives similar effects indicating that increasing the dose will not improve the anti-cancer efficacy of Fronodoside A. The cancer inhibitory effect of Fronodoside A has been observed previously on AsPC-1 pancreatic and MDA-MB-231 xenografts in athymic mice [7,8]. This anti-tumor effect of Fronodoside A may be partly due to its immunostimulatory effect [13] and/or anti-angiogenic effect. In this study, we demonstrated for the first time, that Fronodoside A is a strong anti-angiogenic agent. It reduces the microvessel density (measured by CD31 staining) in the xenografted tumor treated with Fronodoside A and also significantly reverse basal and bFGF induced angiogenesis in the CAM angiogenesis assay. Similarly, Fronodoside A completely suppressed capillary structure formation on Matrigel substratum by human endothelial cells.

Angiogenesis is an attractive target in cancer therapy not only because it supplies oxygen and nutrients for the survival of tumor cells but also provides the route for metastatic spread of these cancer cells. Cancer progression is associated with abrogation of the normal controls that limit cell migration and invasion, leading eventually to metastasis. As metastasis is the major cause of death in cancer patients, the development of new treatment regimens that reduce invasion and metastasis is highly important in cancer therapy. In this context, we demonstrated that Fronodoside A induced a highly significant time- and concentration-dependent inhibition of cell migration, invasion *in vitro* and metastasis *in vivo*. These results are in agreement with our previous study showing that Fronodoside A at concentrations that are not cytotoxic to the cells exerts a strong inhibitory effect on both the migratory and invasive properties of MDA-MB-231 breast cancer cells [7] and with another recent study demonstrating that Fronodoside A inhibits breast cancer metastasis to the lungs [19].

Building on aforementioned results, and knowing from clinical trials that single agent treatments rarely result in clinical benefits to cancer patients, and that combination therapy are necessary for effective treatment of tumors, we investigated the therapeutic advantage of combination of cisplatin, (a first line treatment of lung cancer), with Fronodoside A in nude mice bearing LNM35 xenografts. We found that Fronodoside A enhances the inhibition of lung tumor growth induced by the chemotherapeutic agent cisplatin. These findings identify Fronodoside A as a promising novel therapeutic agent for lung cancer and perhaps other cancers too.

## Acknowledgments

We thank Dr. Mien-Chie Hung from University of Texas MD Anderson Cancer Center for providing the MDA-MB-435 cells and Dr. Katarina Hostanska from Department of Internal Medicine, Institute for Complementary Medicine, University Hospital Zurich, Switzerland for providing the A549 cells.

## Author Contributions

Conceived and designed the experiments: SA ODW. Performed the experiments: SA KA AG MAAS TEA. Analyzed the data: SA MB TEA ODW. Contributed reagents/materials/analysis tools: PC TT. Wrote the paper: SA ODW TEA MB TT.

## References

- Mann J (2002) Natural products in cancer chemotherapy: past, present and future. *Nat Rev Cancer* 2: 143–148.
- Molinski TF, Dalisay DS, Lievens SL, Saludes JP (2009) Drug development from marine natural products. *Nat Rev Drug Discov* 8: 69–85.
- Kuno T, Tsukamoto T, Hara A, Tanaka T (2012) Cancer chemoprevention through the induction of apoptosis by natural compounds. *Journal of Biophysical Chemistry* 3: 156–173.
- Janakiram NB, Mohammed A, Zhang Y, Choi CI, Woodward C, et al. (2010) Chemopreventive effects of Frondanol A5, a *Cucumaria frondosa* extract, against rat colon carcinogenesis and inhibition of human colon cancer cell growth. *Cancer Prev Res (Phila)* 3: 82–91.
- Girard M, Bélanger J, ApSimon JW, Garneau FX, Harvey C, et al. (1990) Fronodoside A. A novel triterpene glycoside from the holothurians *Cucumaria frondosa*. *Can J Chem* 68: 11–18.
- Jin JO, Shastina VV, Shin SW, Xu Q, Park JI, et al. (2009) Differential effects of triterpene glycosides, frondoside A and cucumarioside A2-2 isolated from sea cucumbers on caspase activation and apoptosis of human leukemia cells. *FEBS Lett* 583: 697–702.
- Al Marzouqi N, Iratni R, Nemmar A, Arafat K, Ahmed Al Sultan M, et al. (2011) Fronodoside A inhibits human breast cancer cell survival, migration, invasion and the growth of breast tumor xenografts. *Eur J Pharmacol* 668: 25–34.
- Li X, Roginsky AB, Ding XZ, Woodward C, Collin P, et al. (2008) Review of the apoptosis pathways in pancreatic cancer and the anti-apoptotic effects of the novel sea cucumber compound, Fronodoside A. *Ann N Y Acad Sci* 1138: 181–198.
- Dempke WC, Suto T, Reck M (2010) Targeted therapies for non-small cell lung cancer. *Lung Cancer* 67: 257–274.
- Spira A, Ettinger DS (2004) Multidisciplinary management of lung cancer. *N Engl J Med* 350: 379–392.
- Korpanty G, Smyth E, Carney DN (2011) Update on anti-angiogenic therapy in non-small cell lung cancer: Are we making progress? *J Thorac Dis* 3: 19–29.
- Kozaki K, Miyaishi O, Tsukamoto T, Tatematsu Y, Hida T, et al. (2000) Establishment and characterization of a human lung cancer cell line NCI-H460-LNM35 with consistent lymphogenous metastasis via both subcutaneous and orthotopic propagation. *Cancer Res* 60: 2535–2540.
- Aminin DL, Agafonova IG, Kalinin VI, Silchenko AS, Avilov SA, et al. (2008) Immunomodulatory properties of frondoside A, a major triterpene glycoside from the North Atlantic commercially harvested sea cucumber *Cucumaria frondosa*. *J Med Food* 11: 443–453.
- Aminin DL, Koy C, Dmitrenok PS, Müller-Hilke B, Koczan D, et al. (2009) Immunomodulatory effects of holothurian triterpene glycosides on mammalian splenocytes determined by mass spectrometric proteome analysis. *J Proteomics* 72: 886–906.
- Derycke L, Morbidelli L, Ziche M, De Wever O, Bracke M, et al. (2006) Soluble N-cadherin fragment promotes angiogenesis. *Clin Exp Metastasis* 23: 187–201.
- Harris-Hooker SA, Gajdusek CM, Wight TN, Schwartz SM (1983) Neovascular responses induced by cultured aortic endothelial cells. *J Cell Physiol* 114: 302–310.
- Hait WN (2010) Anticancer drug development: the grand challenges. *Nat Rev Drug Discov* 9: 253–254.
- Roginsky AB, Ding XZ, Woodward C, Ujiki MB, Singh B, et al. (2010) Anti-pancreatic cancer effects of a polar extract from the edible sea cucumber, *Cucumaria frondosa*. *Pancreas* 39: 646–652.
- Ma X, Kundu N, Collin PD, Goloubeva O, Fulton AM (2011) Fronodoside A inhibits breast cancer metastasis and antagonizes prostaglandin E receptors EP4 and EP2. *Breast Cancer Res Treat*.